Advertisement

Tumor Biology

, Volume 34, Issue 1, pp 203–214 | Cite as

Part I. Molecular and cellular characterization of high nitric oxide-adapted human breast adenocarcinoma cell lines

  • B. J. Vesper
  • A. Onul
  • G. K. HainesIII
  • G. Tarjan
  • J. Xue
  • K. M. Elseth
  • B. Aydogan
  • M. B. Altman
  • J. C. Roeske
  • W. A. Paradise
  • H. De Vitto
  • J. A. Radosevich
Research Article

Abstract

There is a lack of understanding of the casual mechanisms behind the observation that some breast adenocarcinomas have identical morphology and comparatively different cellular growth behavior. This is exemplified by a differential response to radiation, chemotherapy, and other biological intervention therapies. Elevated concentrations of the free radical nitric oxide (NO), coupled with the up-regulated enzyme nitric oxide synthase (NOS) which produces NO, are activities which impact tumor growth. Previously, we adapted four human breast cancer cell lines: BT-20, Hs578T, T-47D, and MCF-7 to elevated concentrations of nitric oxide (or high NO [HNO]). This was accomplished by exposing the cell lines to increasing levels of an NO donor over time. Significantly, the HNO cell lines grew faster than did each respective (“PARENT”) cell line even in the absence of NO donor-supplemented media. This was evident despite each “parent” being morphologically equivalent to the HNO adapted cell line. Herein, we characterize the HNO cells and their biological attributes against those of the parent cells. Pairs of HNO/parent cell lines were then analyzed using a number of key cellular activity criteria including: cell cycle distribution, DNA ploidy, response to DNA damage, UV radiation response, X-ray radiation response, and the expression of significant cellular enzymes. Other key enzyme activities studied were NOS, p53, and glutathione S-transferase-pi (GST-pi) expression. HNO cells were typified by a far more aggressive pattern of growth and resistance to various treatments than the corresponding parent cells. This was evidenced by a higher S-phase percentage, variable radioresistance, and up-regulated GST-pi and p53. Taken collectively, this data provides evidence that cancer cells subjected to HNO concentrations become resistant to free radicals such as NO via up-regulated cellular defense mechanisms, including p53 and GST-pi. The adaptation to NO may explain how tumor cells acquire a more aggressive tumor phenotype.

Keywords

Adenocarcinoma Nitric oxide (NO) Nitric oxide synthase (NOS) Breast cancer Reactive Nitrogen Species (RNS) Reactive Oxygen Species (ROS) 

Notes

Acknowledgments

The authors wish to thank the UIC Flow Cytometry facility (Drs. Karen Hagen and Jewel Graves) for their assistance with the FACS study, and the UIC Core Genomics Facility (Dr. Zarema Arbieva and Mr. Oleksiy Karpenko for their assistance with the gene chip study. This work was supported by a Veterans Affairs merit review grant (J.A.R.).

Conflicts of interest

None

References

  1. 1.
    American Cancer Society Inc., Breast Cancer Facts & Figures 2011–2012. Copyright 2011 [Accessed 27 March 2012]; Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-030975.pdf.
  2. 2.
    Jemal A, et al. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011;61(2):69–90.CrossRefGoogle Scholar
  3. 3.
    Bentz BG, et al. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 1999;108(8):781–7.Google Scholar
  4. 4.
    Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;78(6):915–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Singh S, et al. The impact of intracellular generation of nitric oxide on the radiation response of human tumor cells. Radiat Res. 2009;171(5):572–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Paradise WA, Vesper BJ, Goel A, Waltonen JD, Altman KW, Haines III GK, Radosevich JA. Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci. 2010;11:2715–45.PubMedCrossRefGoogle Scholar
  7. 7.
    Vesper BJ, et al. Long-term adaptation of breast tumor cell lines to high concentrations of nitric oxide. Tumor Biol. 2010;31(4):267–75.CrossRefGoogle Scholar
  8. 8.
    Bentz BG, et al. Nitrosative stress induces DNA strand breaks but not caspase mediated apoptosis in a lung cancer cell line. J Carcinog. 2004;3(1):16.PubMedCrossRefGoogle Scholar
  9. 9.
    Bentz BG, et al. Cytoplasmic localization of endothelial constitutive nitric oxide synthase in endometrial carcinomas. Tumor Biol. 1997;18(5):290–300.CrossRefGoogle Scholar
  10. 10.
    Bentz BG, et al. Endothelial constitutive nitric oxide synthase (ecNOS) localization in normal and neoplastic salivary tissue. Head Neck. 1998;20(4):304–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Bentz BG, et al. The kinetics and redox state of nitric oxide determine the biological consequences in lung adenocarcinoma. Tumor Biol. 2007;28(6):301–11.CrossRefGoogle Scholar
  12. 12.
    Bentz BG, et al. The yin and yang of nitric oxide: reflections on the physiology and pathophysiology of NO. Head Neck. 2000;22(1):71–83.PubMedCrossRefGoogle Scholar
  13. 13.
    Keydar I, et al. Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer. 1979;15(5):659–70.PubMedGoogle Scholar
  14. 14.
    Beevi SS, Rasheed MH, Geetha A. Evidence of oxidative and nitrosative stress in patients with cervical squamous cell carcinoma. Clin Chim Acta. 2007;375(1–2):119–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Loibl S, et al. Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. Cancer. 2002;95(6):1191–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Duenas-Gonzalez A, et al. Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. Mod Pathol. 1997;10(7):645–9.PubMedGoogle Scholar
  17. 17.
    Tschugguel W, et al. Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade. Breast Cancer Res Treat. 1999;56(2):145–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Cobbs CS, et al. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1994;55(4):727–30.Google Scholar
  19. 19.
    Chandra R, et al. Expression of nitric oxide synthase type 3 in reflux-induced esophageal lesions. Otolaryngol. Head Neck Surg. 2001;124(4):442–7.CrossRefGoogle Scholar
  20. 20.
    Ambs S, et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 1998;58(2):334–41.PubMedGoogle Scholar
  21. 21.
    Chen YK, Hsue SS, Lin LM. Increased expression of inducible nitric oxide synthase for human buccal squamous-cell carcinomas: immunohistochemical, reverse transcription-polymerase chain reaction (RT-PCR) and in situ RT-PCR studies. Head Neck. 2002;24(10):925–32.PubMedCrossRefGoogle Scholar
  22. 22.
    Hibbs JB, et al. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun. 1988;157(1):87–94.PubMedCrossRefGoogle Scholar
  23. 23.
    Hibbs JB, Vavrin A, Taintor RR. l-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol. 1987;138(2):550–65.Google Scholar
  24. 24.
    Loibl S, et al. The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer. 2005;41(2):265–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Miller, L.P. Quantifying western blots without expensive commercial quantification software. Copyright 2007. [Accessed 20 May 2010]; Available from: http://www.lukemiller.org/journal/2007/08/quantifying-western-blots-.
  26. 26.
    Altman MB, et al. Characterization of a novel phantom for three-dimensional in vitro cell experiments. Phys Med Biol. 2009;54(5):N75–82.PubMedCrossRefGoogle Scholar
  27. 27.
    Natarajan N, et al. Adaptation of the diphenylamine (DPA) assay to a 96-well plate tissue culture format and comparison with the MTT assay. BioTechniques. 1994;17(1):166–71.PubMedGoogle Scholar
  28. 28.
    Smyth, G.K., et al., Limma: Linear Models for Microarray Data. Bioinformatics and computationalbBiology solutions using R and bioconductor, 2005: 397–420.Google Scholar
  29. 29.
    Ritchie ME, et al. A comparison of background correction methods for two-colour microarrays. Bioinformatics. 2007;23(20):2700–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Smyth GK, Speed T. Normalization of cDNA microarray data. Methods. 2003;31(4):265–73.PubMedCrossRefGoogle Scholar
  31. 31.
    Smyth, G.K., Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol, 2004. 3: Article3.Google Scholar
  32. 32.
    Blackett NM, et al. Radiation modifying effect of the free radical norpseudopelletierene-N-oxyl on normal bone marrow stem cells in vitro and in vivo. Radiat Res. 1974;58(3):361–72.PubMedCrossRefGoogle Scholar
  33. 33.
    Bristow, R.G. and R.P. Hill, Molecular and cellular basis of radiotherapy. In I.F. Tannock and R.P. Hill, editors. The basic science of oncology. 1998, McGraw-Hill: New York. p. 95–321.Google Scholar
  34. 34.
    Chen HHW, et al. Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. Int J Radiation Oncology Biol Phys. 2005;63(4):1093–100.Google Scholar
  35. 35.
    Cooke BC, Fielden EM, Johnson M. Polyfunctional radiosensitizers: I. Effects of a nitroxyl biradical on the survival of mammalian cells in vitro. Radiat Res. 1976;65(1):152–62.PubMedCrossRefGoogle Scholar
  36. 36.
    De Ridder M, et al. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide. 2008;19(2):164–9.PubMedCrossRefGoogle Scholar
  37. 37.
    George R, et al. Audio-visual biofeedback for respiratory-gated radiotherapy: impact of audio instruction and audio-visual biofeedback on respiratory-gated radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65(3):924–33.PubMedCrossRefGoogle Scholar
  38. 38.
    Griffin RJ, et al. Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int J Radiat Oncol Biol Phys. 1996;36(2):377–83.PubMedCrossRefGoogle Scholar
  39. 39.
    Hogle WP. Radiation therapy in the treatment of breast cancer. Semin Oncol Nurs. 2007;23(1):20–8.Google Scholar
  40. 40.
    American Cancer Society, I. Oral Cancer. Copyright 2008 [Accessed 17 June 2012]; Available from: http://www.cancer.org/downloads/PRO/OralCancer.pdf.
  41. 41.
    Wang YZ, et al. Expression of nitric oxide synthase in human gastric carcinoma and its relation to p53, PCNA. World J Gastroenterol. 2005;11(1):46–50.PubMedGoogle Scholar
  42. 42.
    Glynn, S., et al., iNOS expression is associated with basal-like breast cancer phenotype and predicts poor survival in ERneg breast cancer. Nitric Oxide, 2007. 17(Supp. 1): S17.Google Scholar
  43. 43.
    Nakamura Y, et al. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res. 2006;12(4):1201–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Thomsen LL, et al. Nitric oxide synthase in human breast cancer. Br J Cancer. 1995;72(1):41–4.Google Scholar
  45. 45.
    Bulut AS, et al. Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases. Virchows Arch. 2005;447(1):24–30.PubMedCrossRefGoogle Scholar
  46. 46.
    Masri FA, et al. Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med. 2005;172(5):597–605.PubMedCrossRefGoogle Scholar
  47. 47.
    Lee TW, et al. Differential expression of inducible nitric oxide synthase and peroxisome proliferator-activated receptor gamma in non-small cell lung carcinoma. Eur J Cancer. 2003;39(9):1296–301.PubMedCrossRefGoogle Scholar
  48. 48.
    Liu CY, et al. Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer. 1998;78(4):534–41.PubMedCrossRefGoogle Scholar
  49. 49.
    Rosbe KW, et al. Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. otolaryngol. Head Neck Surg. 1995;113(5):541–9.Google Scholar
  50. 50.
    Yarmolyuk Y, et al. A model system for dtudying nitric oxide in tumors: high nitric oxide-adapted head and neck squamous cell lines. Tumor Biol. 2011;32(1):77–85.CrossRefGoogle Scholar
  51. 51.
    Bentz BG, et al. Nitric oxide and apoptosis during human head and neck squamous cell carcinoma development. Am J Otolaryngol. 2002;23(1):4–11.PubMedCrossRefGoogle Scholar
  52. 52.
    Gavilanes J, et al. Nitric oxide synthase activity in human squamous cell carcinoma of the head and neck. Laryngoscope. 1999;109(1):148–52.PubMedCrossRefGoogle Scholar
  53. 53.
    Bentz BG, Haines III GK, Radosevich JA. Glutathione S-transferase pi in squamous cell carcinoma of the head and neck. Laryngoscope. 2000;110(10 Pt 1):1642–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Cullen KJ, et al. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res. 2003;63(23):8097–102.PubMedGoogle Scholar
  55. 55.
    Shiga H, et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res. 1999;5(12):4097–104.PubMedGoogle Scholar
  56. 56.
    Dourado DF, Fernandes A, Ramos MJ. Mammalian cytosolic glutathione transferases. Curr Protein Pept Sci. 2008;9(4):325–37.PubMedCrossRefGoogle Scholar
  57. 57.
    Mulder TP, et al. Glutatione S-transferases and glutathione in human head and neck cancer. Carcinogenesis. 1995;16(3):619–24.PubMedCrossRefGoogle Scholar
  58. 58.
    De Vitto, et al. Part II. Mitochondrial mutational status of high nitric oxide adapted cell line BT-20 (BT-20-HNO) as it relates to human primary breast tumors. Tumor Biol. 2012. doi: 10.1007/s13277-012-0555-4.
  59. 59.
    De Vitto, et al. Part III. Molecular changes induced by high nitric oxide adaptation in human breast cancer cell line BT-20 (BT-20-HNO): a switch from aerobic to anaerobic. Tumor Biol. 2012. doi: 10.1007/s13277-012-0564-3.

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • B. J. Vesper
    • 1
    • 2
  • A. Onul
    • 1
    • 2
  • G. K. HainesIII
    • 3
  • G. Tarjan
    • 4
  • J. Xue
    • 1
    • 2
  • K. M. Elseth
    • 1
    • 2
  • B. Aydogan
    • 5
    • 6
  • M. B. Altman
    • 5
    • 6
  • J. C. Roeske
    • 7
  • W. A. Paradise
    • 1
    • 2
  • H. De Vitto
    • 1
    • 2
    • 8
  • J. A. Radosevich
    • 1
    • 2
    • 9
  1. 1.Center for Molecular Biology of Oral DiseasesUniversity of Illinois at Chicago, College of DentistryChicagoUSA
  2. 2.Department of Oral Medicine and Diagnostic SciencesUniversity of Illinois at ChicagoChicagoUSA
  3. 3.Department of PathologyYale University School of MedicineNew HavenUSA
  4. 4.Department of PathologyJohn H. Stroger, Jr. Hospital of Cook CountyChicagoUSA
  5. 5.Department of Radiation and Cellular OncologyUniversity of ChicagoChicagoUSA
  6. 6.Department of Radiation OncologyUniversity of Illinois at ChicagoChicagoUSA
  7. 7.Department of Radiation OncologyLoyola University Medical CenterMaywoodUSA
  8. 8.Universidade Federal do Rio de JaneiroIBqMBrazil
  9. 9.Jesse Brown VAMCChicagoUSA

Personalised recommendations